Compare Organon & Co. Common Stock (OGN) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Starbucks Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Starbucks Corp trades at $94 (market cap $104.88B). The key difference: Starbucks Corp is far larger — about 29× Organon & Co. Common Stock's market cap, and Starbucks Corp pays the higher dividend (2.74%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Starbucks Corp for 190 Days on average.
| OGN | SBUX | |
|---|---|---|
Market Cap | $3.62B | $104.88B |
Volume | 2,892,999 | 9,749,448 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $108.55 |
52-Week Low | $5.70 | $79.60 |
Typical Hold Time | 0 Days | 190 Days |
Enterprise Value | $11.04B | $123.70B |
Dividend Yield | 0.58% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Starbucks (SBUX) trades at $92.00, down 0.31% on the day, with technical indicators showing bearish momentum. The company reported mixed quarterly results, missing Q4 2025 EPS estimates but beating in Q1 and Q2 2026. Recent news highlights store closures and strategic restructuring, while analyst consensus remains positive with a $115.50 price target. Financial trends show revenue growth to $37.18B in 2025 but declining net income margins from 11.46% in 2023 to 4.99% in 2025.
SBUX faces execution risks from store optimization and labor relations, but strong brand equity and analyst buy ratings suggest long-term recovery potential. The stock's high P/E ratio of 53.18 indicates premium valuation expectations. Near-term pressure from restructuring costs contrasts with dividend stability and international expansion opportunities through partnerships in Asia.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
